Cantor Fitzgerald Maintains Overweight on ALX Oncology Holdings, Lowers Price Target to $18
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Alethia Young has maintained an Overweight rating on ALX Oncology Holdings (NASDAQ:ALXO) but lowered the price target from $22 to $18.
August 14, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Cantor Fitzgerald has maintained an Overweight rating on ALX Oncology Holdings but lowered the price target from $22 to $18.
The lowering of the price target by Cantor Fitzgerald could potentially lead to a decrease in the stock price of ALX Oncology Holdings in the short term as it indicates a lower expected value of the company's stock. However, the maintained Overweight rating suggests that the analyst still believes the company's stock is expected to outperform.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100